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Renal cell cancer is the commonest malignant tumour of the adult
kidney accounting for about 85% of malignant kidney tumours
and the incidence of this tumour is steadily rising (Stadler and
Vogelzang, 1993; Motzer et al, 1996). The aetiology and patho-
genesis of renal cell cancer is not fully understood, although
several environmental risk factors have been proposed, including
smoking, occupational exposure to heavy metals (e.g. cadmium
and arsenic) and obesity. The majority of renal cell cancers are
considered to develop from proximal tubular epithelium. Renal
cell cancer also responds poorly to wide variety of anti-cancer
drugs including vinca alkaloids, etoposide, anthracyclines, taxanes
and mitomycin-C (Chapman and Goldstein, 1995; Motzer et al,
1996). Furthermore, agents such as cyclosporin which reverse P-
glycoprotein-associated multidrug resistance have not been shown
to enhance anti-tumour activity in renal cell cancer (Yagoda et al,
1995).
The cytochromes P450 (P450s) are a very large gene family of
constitutive and inducible haem containing enzymes. The P450s
are classified into families, sub-families and individual forms
according to gene sequence homology (individual P450s are
identified by the prefix CYP and current P450 nomenclature is
outlined in Nelson et al, 1996). There are two broad groups of
mammalian P450s. A large group of P450s whose primary role is
the oxidative activation and/or deactivation of a wide variety of
xenobiotics (CYP1, CYP2, CYP3) while there is a much smaller
group of P450s which are constitutively expressed in endocrine
glands (adrenal gland, ovary testis) where they are specifically
involved in steroid hormone synthesis. Those P450s that have
been primarily characterized according to their ability to meta-
bolize xenobiotics are also capable of metabolizing endogenous
compounds especially eicosanoids (Capdevila et al, 1992) and
steroid hormones (Sarabia et al, 1997) and thus those P450s may
also have endogenous functions particularly involvement in cell
regulation and cell signalling (Nebert, 1994).
The P450s are considered to have a central role in chemical
carcinogenesis and are involved in tumour initiation and promo-
tion as they can activate or deactivate many carcinogens (Kawajiri
and Fujii-Kuriyama, 1991; Guengerich 1992; Gonzalez and
Gelboin, 1994). Furthermore, the P450s can influence the
response of established tumours to anti-cancer drugs as P450s are
involved in the metabolism of several anti-cancer drugs (Kivistö et
al, 1995a).
The CYP3A P450 family is one of the main P450 families
involved in xenobiotic metabolism including the metabolism of
various carcinogens (Gonzalez and Gelboin, 1994; Roberts-
Thomson et al, 1995) and several current anti-cancer drugs
(Kivistö et al, 1995a). This family of P450s consists of three
closely related forms: CYP3A4, CYP3A5 and CYP3A7. CYP3A4
is the major form of P450 which is constitutively expressed in
liver whereas CYP3A5 is only found in a minority of liver
samples. However, CYP3A5 appears to show a more widespread
constitutive expression in extrahepatic tissues while CYP3A7 is
the main form of P450 found in fetal liver (Kitada and Kamataki,
1994).
Several studies have identified the presence of CYP3A in
tumours, including breast cancer (Murray et al, 1993), colon
cancer (Massaad et al, 1992), lung cancer (Kivistö et al, 1995b)
and stomach cancer (Murray et al, 1998) however, no studies to
date have investigated the presence of CYP3A in renal cancer. In
this study the presence and localization of CYP3A has been inves-
tigated by a combination of immunohistochemistry, immunoblot-
ting and reverse transcriptase polymerase chain reaction (RT-PCR)
in primary renal cell cancer and normal human kidney.
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Summary Renal cell cancer is the main malignant tumour of the kidney and has an increasing incidence. This type of tumour has a poor
prognosis and shows intrinsic resistance to several anti-cancer drugs. The CYP3A P450 family, which consists of three closely related forms,
is involved in the oxidative activation and deactivation of a variety of carcinogens and several anti-cancer drugs. In this study the presence
and cellular localization of CYP3A has been investigated using a combination of immunohistochemistry, immunoblotting and reverse
transcriptase polymerase chain reaction (RT-PCR) in renal cell cancer and corresponding normal kidney. CYP3A was consistently expressed
in both renal call cancer and in normal kidney. In renal cell cancer, CYP3A was localized to tumour cells and in normal kidney the predominant
cellular localization of CYP3A was to proximal tubular epithelial cells. RT-PCR showed that both CYP3A5 mRNA and CYP3A7 mRNA were
consistently present in both tumour and normal samples, while CYP3A4 mRNA was present in 65% of tumours and 90% of normal samples.
This study indicates that individual members of the CYP3A family are expressed in renal cell cancer. The presence of CYP3A in renal cell
cancer might be important in the metabolic potentiation as well as the detoxification of chemotherapeutic agents used to renal cancer.
Keywords: cytochrome P450; kidney; neoplasm
1836
British Journal of Cancer (1999) 79(11/12), 1836–1842
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0292
Received 19 May 1998
Revised 20 August 1998
Accepted 26 August 1998
Correspondence to: GI MurrayCYP3A in renal cancer 1837
British Journal of Cancer (1999) 79(11/12), 1836–1842 © Cancer Research Campaign 1999
MATERIALS AND METHODS
Tissue
Paired samples of renal cancer and corresponding normal kidney
were obtained from 20 adult patients (15 male, five female) under-
going surgery for primary renal cancer and submitted to the
Department of Pathology, University of Aberdeen, for diagnosis.
None of the patients had received chemotherapy prior to surgery.
All the tumours were primary renal cell cancers and histological
classification of the tumours performed according to current
criteria (Kovacs et al, 1997) showed 17 clear cell carcinomas,
two chromophobe carcinomas and one papillary carcinoma. The
clinicopathological data for each patient are summarized in
Table 1.
When the tissue samples were prepared they were carefully
selected and dissected to ensure no contamination by connective
tissue or fat and the tumour samples were selected from areas of
macroscopically viable tumour. Areas of necrotic tumour or haem-
orrhage were avoided. As far as possible, the tumour samples were
selected from areas of viable tumour of high tumour cellularity
(confirmed by microscopy of haematoxylin and eosin stained
section) and contained only a very small proportion of non-tumour
cells (either inflammatory cells or stromal cells). This is important
when interpreting the results of any investigation that involves
homogenization of tumours, since tumour samples can consist of a
variable proportion of tumour and non-tumour cells. Furthermore,
any adjacent normal renal tissue was also removed from tumour
samples prior to sample preparation.
Small blocks of normal and tumour kidney were fixed in 10%
neutral-buffered formalin and embedded in wax for histological
diagnosis and immunohistochemistry. Samples of both normal
and viable tumour kidney were also frozen in liquid nitrogen for
protein and RNA analysis and stored at –75°C prior to use.
Immunohistochemistry
CYP3A immunoreactivity was identified using a monoclonal anti-
body (HL3) which recognizes CYP3A4, CYP3A5 and CYP3A7
(Murray et al, 1987, 1988). Sections (4 mm in thickness) of normal
and tumour kidney were dewaxed in xylene, rehydrated in alcohol
and washed in 0.05 M Tris-HCl pH 7.6 containing 150 mM sodium
chloride (TBS). The primary antibody was applied as undiluted
tissue culture supernatant for 60 min at room temperature. Rabbit
anti-mouse immunoglobulin (1/100, Dako, High Wycombe, UK)
and monoclonal APAAP (1/100, Dako) were subsequently applied
(McKay et al, 1995). Following incubation with each antibody the
sections were washed for three 5-min periods in TBS to remove
unbound antibody. Sites of bound alkaline phosphatase were
demonstrated colorimetrically using a solution containing 3 mg
bromo-chloro-indolyl phosphate (Sigma, Poole, Dorset, UK),
10 mg nitro blue tetrazolium (Sigma), 6 mg sodium azide and
4 mg levamisole (Sigma) in 10 ml 0.05 M Tris-HCl buffer pH 9.0
containing 0.2% magnesium chloride (MgCl2). After incubating
the sections for 30 min at room temperature, the enzyme reaction
was stopped by washing the sections for 5 min in cold tap water.
The slides were then counterstained with haematoxylin, air-dried
and mounted in glycerine jelly. The sections were examined using
bright field light microscopy in order to establish the presence or
absence of immunostaining, and its distribution. TBS in place of
the primary antibody was used as a negative control while normal
adult human liver which had been obtained from partial hepatec-
tomy specimens and fixed in formalin was used as a positive
control.
Preparation of microsomes
Frozen samples of normal kidney and kidney tumour were thawed
on ice in 0.01 M Tris-HCl pH 7.4 containing 1.15% potassium
chloride. Once thawed the tissue was homogenized in 0.01 M
Tris-HCl containing 0.25 M sucrose and 15% glycerol using a
Polytron PT3000 homogenizer (Kinematica AG, Switzerland).
The crude homogenates were centrifuged at 15 000 g for 20 min at
4°C using a Centrikon T-124 centrifuge (Kontron Instruments,
Cumbernauld, UK). The resultant supernatants were then
centrifuged at 180 000 g (44 000 rpm) for 1 h at 4°C using a
Centrikon T-1160 centrifuge (Kontron Instruments). The pellet
obtained after centrifugation was resuspended in 0.1 M Tris-HCl
containing 15% glycerol and 1 mM EDTA (Sigma) and centrifuged
again at 180 000 g (44 000 rpm) for 1 h at 4°C. The final micro-
somal pellet was resuspended in 0.1 M Tris-HCl containing 15%
glycerol and 1 mM EDTA, and the microsomes were then stored at
–75°C prior to use. The protein concentration of each sample of
microsomes was determined using Bradford’s method (Bradford,
1976).
Immunoblotting
Microsomal proteins (30 mg of protein were loaded per lane for
each kidney sample) were electrophoretically separated at constant
current in a 10% polyacrylamide gel using a Hoefer SE600 elec-
trophoresis system (Hoefer Pharmacia Biotechnology Inc., MN,
USA) and then transferred at constant current for 18 h to nitrocel-
lulose (Hybond ECL, Amersham Life Sciences, Little Chalfont,
UK) by electroblotting using a Hoefer TE42 blotting system
(Hoefer Pharmacia Biotechnology). Non-specific binding sites
Table 1 Clinicopathological details of patients
Case no. Age Sex Histopathology of renal cancer TNM stage
1 67 M Clear cell 2
2 63 M Chromophobe 2
3 60 M Clear cell 3
4 48 F Chromophobe 2
5 78 F Clear cell 2
6 59 M Clear cell 3
7 52 M Clear cell 3
8 39 F Clear cell 3
9 72 F Clear cell 3
10 88 M Clear cell 3
11 68 M Papillary 2
12 66 M Clear cell 3
13 42 M Clear cell 2
14 71 M Clear cell 2
15 78 M Clear cell 2
16 82 M Clear cell 2
17 58 M Clear cell 2
18 39 F Clear cell 2
19 45 M Clear cell 3
20 63 M Clear cell 2
M, male; F, female.1838 GI Murray et al
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were blocked by incubation of the nitrocellulose membrane for
60min at room temperature in wash buffer consisting of 2% non-
fat milk (Marvel, Premier Beverages, Stafford, UK) in 10mM
phosphate-buffered saline (PBS) containing 0.05% Tween 20
(Sigma). The nitrocellulose was then sequentially incubated with
anti-CYP3A antibody (1/1000) and goat anti-rabbit immunoglob-
ulin conjugated to horseradish peroxidase (1/2000; Bio-Rad,
Hemel Hempstead, UK). This polyclonal antibody also recognizes
CYP3A4, CYP3A5 and CYP3A7 (Shaw et al, 1989) and is more
effective by immunoblotting than the monoclonal antibody used
for immunohistochemistry. After each antibody application the
membrane was washed for five 10-min periods with the wash
buffer and after removal of unbound secondary antibody the
membrane was further washed in 10mMPBS for five 10-min
periods. Horseradish peroxidase was then demonstrated using an
enhanced chemiluminescent technique (Amersham Life Sciences)
which was performed as previously described (McKay et al, 1995;
Murray et al, 1997).
Microsomes prepared from human lymphoblastoid cells which
contained either expressed human CYP3A4 or CYP3A5 were used
as positive controls and were obtained from Gentest Corp,
Woburn, MA, USA.
Isolation of RNA
Total RNA from kidney samples was isolated using RNAzol B
(Biogenesis Ltd, Poole, Dorset, UK) used according to the manu-
facturer’s instructions. The isolated RNA was resuspended in
diethyl pyrocarbonate (DEPC, Sigma) treated water and quantified
spectrophotometrically at 260nm and 280nm respectively. All the
RNA samples had 260:280 ratios between 1.8 and 2.0.
cDNA synthesis
Synthesis of cDNA was performed with a reverse transcriptase kit
(Promega, Southampton, UK) using the following reaction condi-
tions as recommended by Promega: 1mg of RNA, 1 ´reverse
transcriptase buffer (10mMTris-HCl, pH 8.8, 50mMpotassium
chloride and 0.1% Triton X-100), 5mMMgCl2, 1mMof each
dNTP, 0.5 unit ribonuclease inhibitor, 15 units of avian myelo-
blastosis reverse transcriptase and 0.5mg oligo dT15 primer in a
final volume of 20ml. Synthesis of cDNA was performed at 42°C
for 60min and the reaction was stopped by heating to 99°C for
5min followed by chilling on ice. The cDNA was then stored
at –75°C until required.
PCR
PCR was carried out in 50-ml reaction volumes with the following
reaction conditions: 2ml of cDNA, 10mMTris-HCl (pH 8.3),
50mMpotassium chloride, 0.25 units of Amplitaq Gold (PE
Applied Biosystems, Warrington, UK), 400mMdNTP (Promega)
and 2.5mMMgCl2 (b-actin), 3mMMgCl2 (CYP3A7) or 3.5mM
MgCl2 (CYP3A4 and CYP3A5). The amount of each primer in the
PCR reaction was 80pmol for b-actin and 85pmol for each P450
primer. All the P450 oligonucleotide primers were obtained from
Life Technologies (Paisley, Renfrewshire, UK) while the b-actin
oligonucleotide primers were purchased from Stratagene,
Cambridge, UK. The oligonucleotide primer sequences,
nucleotide location and expected product size for CYP3A4,
CYP3A5, CYP3A7 and b-actin are detailed in Table 2. PCR with
Amplitaq gold requires an initial precycling step at 95°C for
15min to activate the enzyme prior to commencing the thermo-
cycling. The following thermocycling conditions (as recom-
mended by Stratagene) were used for b-actin: 94°C for 5min,
60°C for 5min followed by 40 cycles of amplification consisting
of 72°C for 90s, 94°C for 48s, 60°C for 48s and a final 72°C
extension for 10min. The thermocycling parameters for CYP3A4,
CYP3A5 and CYP3A7 were: 40 cycles of amplification consisting
of 94°C for 30s, 60°C for 30s and 72°C for 60s, followed by a
final 2-min extension at 72°C. Both negative and positive controls
were included in each PCR reaction. The negative control was
DEPC-treated water in place of the template cDNA. The positive
controls for both CYP3A4 and CYP3A5 was cDNA prepared from
total RNA isolated from normal adult human liver previously
shown to contain CYP3A4 and CYP3A5 (McFadyen et al, 1998)
while the positive control for CYP3A7 was cDNA prepared from
total RNA isolated from human fetal liver (the gestational age of
the fetus was 16 weeks). The PCR products (10ml) were separated
by gel electrophoresis using a 1.5% agarose gel, stained with
ethidium bromide (Sigma) and visualized by trans-illumination
with ultra-violet light. The gels were photographed with Polaroid
type 665 black and white film.
Sequencing of PCR products
Fluorescence-based DNA sequencing was performed to confirm
the identity of the individual PCR products. PCR samples were
purified for sequencing by using centricon C-100 columns
(Amicon, Gloucester, UK) and approximately 150ng of template
were sequenced using a Taqdye deoxy terminator sequencing kit
Table 2 Oligonucleotide primer sequences for CYP3A4, CYP3A5, CYP3A7 and b-actin
P450 Primer sequence ( 5¢to 3¢) Nucleotide  Product  GenBank
location  size accession
(bp) no.
CYP3A4 Forward CTGTGTGTTTCCAAGAGAAGTTTAC 782–805 742 M14096
Reverse TGGTTGAAGAAGTCCTCCTAAG 1523–1502
CYP3A5 Forward GTCTCTCTGTTTCCAAAAGATACC 799–822 737 J04813
Reverse TGAAGAAGTCCTTGCGTGTC 1535–1516
CYP3A7 Forward CTATGATACTGTGCTACAGT 1041–1060 474 D00408
Reverse TCAGGCTCCACTTACGGTCT 1496–1515
b-actin Forward TGACGGGGTCACCCACACTGTGCCCATCTA 1038–1067 661 X00351
Reverse CTAGAAGCATTGCGGTGGACGATGGAGGG 1876–1905CYP3A in renal cancer 1839
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using the protocol recommended by the manufacturer (PE Applied
Biosystems, Warrington, UK). Amplification products from the
PCR were sequenced directly using an Applied Biosystems model
373A automated DNA sequencer.
RESULTS
Immunohistochemistry
Strong immunoreactivity for CYP3A was identified in every renal
tumour and immunostaining was specifically localized to the cyto-
plasm of tumour cells (Figure 1). There was no significant differ-
ence in the intensity of immunoreactivity in the different
histological types of renal cell cancer (Figure 1). In normal kidney
strong CYP3A immunoreactivity was identified in the proximal
tubular epithelial cells (Figure 2A) while there was weak CYP3A
immunoreactivity in distal tubular epithelial cells. There was no
immunoreactivity for CYP3A in glomeruli (Figure 2A). In the
medulla there was strong staining in collecting duct epithelium
(Figure 2B).
A
C
B
Figure 1 Localization of CYP3A in different histological types of renal
cancer: (A) clear cell cancer, (B) renal cell cancer of chromophobe type and
(C) papillary cancer. In each type of tumour there is strong CYP3A
immunoreactivity in the cytoplasm of tumour cells (arrows identify CYP3A
immunoreactive tumour cells)1840 GI Murray et al
British Journal of Cancer (1999) 79(11/12), 1836–1842 © Cancer Research Campaign 1999
Immunoblotting
Immunoblotting of microsomes prepared from kidney tumour
samples showed the presence of CYP3A in every tumour sample
(Figure 3). Similarly, immunoblotting of microsomes from normal
kidney also showed the presence of CYP3A in each sample of
normal kidney. The intensity of the immunoreactive band in the
tumours was at least as strong as that observed in the corre-
sponding normal samples.
RT-PCR
All the samples of both tumour and normal kidney amplified for
b-actin and were subjected to PCR for CYP3A4, CYP3A5 and
CYP3A7. CYP3A5 and CYP3A7 were consistently identified in
all the tumour and normal samples (Figure 4). There was no
apparent variation in the intensity of the amplified band observed
in the corresponding normal and tumour samples for either
CYP3A5 or CYP3A7. CYP3A4 mRNA was identified in 90%
(18) of normal kidney samples and only in 65% (13) of the tumour
samples. The tumours which did not show the presence of
CYP3A4 mRNA were five clear cell carcinomas and the single
papillary carcinoma. Both the normal samples in which CYP3A4
was not detected showed the presence of CYP3A4 in the corre-
sponding tumour samples. Sequencing of the PCR products
confirmed identity with the appropriate P450.
A
B
Figure 2 Immunohistochemical localization of CYP3A in normal kidney:
(A) renal cortex, (B) medulla. In the cortex there is strong CYP3A
immunoreactivity in proximal tubular epithelial cells while there is no
immunostaining in glomeruli. In the medulla there is strong immunoreactivity
for CYP3A in collecting duct epithelium.
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Figure 3 Immunoblot of CYP3A of representative paired samples of normal
kidney and kidney cancer. Lane 1 expressed CYP3A4 (10 mg of microsomal
protein, 0.51 pmol of P450), lane 2 expressed CYP3A5 (2 mg of microsomal
protein, 0.78 pmol of P450), lanes 3, 5, 7, 9 and 11 normal kidney; lanes 4, 6,
8, 10 and 12 corresponding kidney cancer samples (all clear cell
carcinomas). A total of 30 mg of microsomal protein were loaded for each
kidney sample
Figure 4 Analysis of representative CYP3A4, CYP3A5, CYP3A7 and
b-actin PCR products. Lanes 1 and 16 molecular size markers (100 bp
ladder); lanes 2, 4, 6, 8, 10 and 12 normal kidney; lanes 3, 5, 7, 9, 11 and 13
corresponding kidney cancer samples (all clear cell carcinomas); lane 14
negative control and lane 15 positive controlDISCUSSION
The human CYP3A P450 family consists of three closely related
forms. CYP3A4 is the major form of P450 present in adult human
liver, whereas CYP3A5 is only found in approximately 20–25%
of livers (Schuetz et al, 1994). However, CYP3A5 appears to be
more commonly present in extrahepatic tissues and has been
identified in several normal tissues including colon (McKinnon
et al, 1995), lung (Anttila et al, 1997), polymorphonuclear leuco-
cytes (Janardan et al, 1996) and anterior pituitary gland (Murray
et al, 1995) while CYP3A7 is the main form of P450 found in
human fetal liver (Kitada and Kamataki, 1994). CYP3A can
metabolize a variety of carcinogens (Gonzalez and Gelboin, 1994)
and several anticancer drugs in clinical use, including ifosphamide
(Chang et al, 1993; Walker et al, 1994) and paclitaxel (Harris et al,
1994). Thus there is potential involvement of CYP3A in both renal
carcinogenesis and the response of established renal tumours to
therapy.
CYP3A has previously been identified in various types of
malignant tumours including breast cancer (Murray et al, 1993),
colon cancer (Gervot et al, 1996), primary and secondary tumours
of liver (Fritz et al, 1993), lung cancer (Kivistö et al, 1995b, 1996)
and stomach cancer (Murray et al, 1998). The frequency of identi-
fication of CYP3A in the individual types of tumours has been
different. However, the presence of CYP3A has not been pre-
viously investigated in renal tumours, although kidney tumours
have been previously shown to express CYP1B1 (Murray et al,
1997) and microsomal epoxide hydrolase (McKay et al, 1995).
The individual members of the CYP3A family have almost
identical molecular sizes and electrophoretic mobilities as judged
by SDS-PAGE. Therefore, the strategy that was adopted to deter-
mine the presence and cellular localization of these forms of P450
in renal cell cancer and normal kidney was threefold: immunohis-
tochemistry was used to identify the cellular localization of P450,
immunoblotting to confirm the presence of immunoreactive
CYP3A and RT-PCR to identify specifically CYP3A4, CYP3A5
and CYP3A7 mRNA. The CYP3A antibodies used in this study
recognize CYP3A4, CYP3A5 and CYP3A7 and, because of their
almost identical molecular size, it was not possible to resolve sepa-
rate immunoreactive bands by immunoblotting. Thus RT-PCR was
used to identify the presence of individual P450s of the CYP3A
family. In each case the identity of the PCR product was confirmed
by fluorescence-based sequencing.
Immunohistochemistry established that CYP3A was specifi-
cally localized to renal cancer cells. The direct demonstration by
immunohistochemistry that CYP3A is expressed in tumour cells is
important when considering the possible clinical consequences of
CYP3A in renal tumours. The consistent expression of CYP3A in
all renal tumours is at a much higher frequency than has been
reported for the frequency of expression of CYP3A in some other
types of tumour (Fritz et al, 1993; Kivistö et al, 1995b; Murray
et al, 1998).
Previous studies have indicated that both CYP3A4 and
CYP3A5 have been identified in normal kidney (Schuetz et al,
1992; Haehner et al, 1996) with CYP3A5 being present more
frequently than CYP3A4 and possibly also quantitatively in larger
amounts (Haehner et al, 1996). The consistent expression of
CYP3A7 mRNA in the normal samples of kidney is at a much
higher frequency than that observed by Haehner et al (1996)
although CYP3A7 mRNA was frequently identified in normal
adult lung tissue (Kivistö et al, 1996)
Renal cell cancer is considered to develop from proximal
tubular epithelial cells (Motzer et al, 1996) and the presence of
CYP3A in normal proximal tubular epithelium suggests that it
may be involved in tumour development. The consistent expres-
sion of CYP3A in renal tumours is another indicator that this type
of tumour expresses a phenotype associated with normal proximal
tubular epithelium. Furthermore, the expression of individual
forms of CYP3A in the kidney tumours suggest that these forms of
P450 may contribute to the intrinsic multidrug resistance that is
observed in this type of tumour (Chapman and Goldstein, 1995).
The selection of anticancer drugs to treat kidney cancer should be
considered in light of this study with avoidance of those agents
which are significantly deactivated by these forms of P450.
Paradoxically, because of the dual role of P450s in both activating
and deactivating xenobiotics, the presence of CYP3A in kidney
cancer may also provide molecular targets for certain anticancer
drugs. One anticancer agent that is of particular interest is AQ4N,
an alkylaminoanthroquinone, which is an inhibitor of both
topoisomerase-I and topoisomerase-II (Patterson, 1993). This
compound is activated by CYP3A and in hypoxic conditions,
which are likely to exist in tumours, produces a cytotoxic metabo-
lite of high potency, whereas in norm-oxic conditions, present in
normal tissues, there is no cytotoxicity (Patterson, 1993). Use of
this compound could be considered in the treatment of kidney
cancer as all the tumours show significant expression of CYP3A.
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